HomeCompareKARBF vs EPRT

KARBF vs EPRT: Dividend Comparison 2026

KARBF yields 38.10% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KARBF wins by $145.5K in total portfolio value
10 years
KARBF
KARBF
● Live price
38.10%
Share price
$5.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$208.9K
Annual income
$33,891.10
Full KARBF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — KARBF vs EPRT

📍 KARBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKARBFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KARBF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KARBF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KARBF
Annual income on $10K today (after 15% tax)
$3,238.10/yr
After 10yr DRIP, annual income (after tax)
$28,807.43/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, KARBF beats the other by $17,892.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KARBF + EPRT for your $10,000?

KARBF: 50%EPRT: 50%
100% EPRT50/50100% KARBF
Portfolio after 10yr
$136.1K
Annual income
$23,365.91/yr
Blended yield
17.16%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

KARBF
No analyst data
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KARBF buys
0
EPRT buys
0
No recent congressional trades found for KARBF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKARBFEPRT
Forward yield38.10%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$208.9K$63.4K
Annual income after 10y$33,891.10$12,840.73
Total dividends collected$154.9K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: KARBF vs EPRT ($10,000, DRIP)

YearKARBF PortfolioKARBF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$14,510$3,809.52$11,205$505.18+$3.3KKARBF
2$20,691$5,165.83$12,672$682.46+$8.0KKARBF
3$29,024$6,884.70$14,490$930.48+$14.5KKARBF
4$40,081$9,025.64$16,786$1,282.69+$23.3KKARBF
5$54,536$11,648.73$19,753$1,791.56+$34.8KKARBF
6$73,166$14,812.69$23,677$2,541.64+$49.5KKARBF
7$96,860$18,572.81$29,008$3,672.99+$67.9KKARBF
8$126,620$22,978.99$36,463$5,425.08+$90.2KKARBF
9$163,557$28,073.84$47,238$8,221.57+$116.3KKARBF
10$208,897$33,891.10$63,385$12,840.73+$145.5KKARBF

KARBF vs EPRT: Complete Analysis 2026

KARBFStock

Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally. It offers skin health products under the Remescar, Locobase, Decubal, and indy beauty brand names; intimate health products under the Pevaryl, Multi Gyn, Asan, and Selexid brand names; and foot health products under the Pevaryl, CCS, Nailner, and wortie brands. The company also provides pain, cough, and cold products under the Paracet, Ibux, Mollipect, and Viruseptin brand names; prescription drugs under the Burinex, Centyl, Kaleorid, and Lithionit brands; and wellness products under the nutravita, Alpha Foods, Flux, Allévo, Dosett, Dax, and Lactocare brands. It sells its products in approximately 90 countries with Europe and the Nordic region markets through direct sales organizations and a network of distributors, as well as online. The company was formerly known as Karo Bio AB (publ) and changed its name to Karo Pharma AB (publ) in March 2016. Karo Pharma AB (publ) was incorporated in 1987 and is headquartered in Stockholm, Sweden.

Full KARBF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this KARBF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KARBF vs SCHDKARBF vs JEPIKARBF vs OKARBF vs KOKARBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.